Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials

Published:December 01, 2014DOI:https://doi.org/10.1016/j.jaad.2014.10.014


      Standard-dose (36-Gy) total skin electron beam therapy (TSEBT) is a highly effective treatment in mycosis fungoides. However, the regimen is time-intensive and may be associated with significant toxicity.


      We sought to evaluate the efficacy and tolerability associated with low-dose (12-Gy) TSEBT.


      Data from 3 clinical trials using low-dose (12-Gy) TSEBT were pooled. In all trials, TSEBT-naïve patients with stage IB to IIIA mycosis fungoides were treated with TSEBT (12 Gy, 1 Gy per fraction over 3 weeks). The primary end point was clinical response rate. Secondary end points included time to response and duration of clinical benefit.


      In all, 33 patients enrolled. Eighteen were male; stages were 22 IB, 2 IIA, 7 IIB, and 2 IIIA. Overall response rate was 88% (29/33), including 9 patients with complete response. Median time to response was 7.6 weeks (3-12.4 weeks). Median duration of clinical benefit was 70.7 weeks (95% confidence interval 41.8-133.8 weeks). Toxicities from TSEBT were mild and reversible.


      Conclusions are limited because of the small number of patients.


      Low-dose TSEBT provides reliable and rapid reduction of disease burden in patients with mycosis fungoides, which could be administered safely multiple times during the course of a patient's disease with acceptable toxicity profile.

      Key words

      Abbreviations used:

      AE ( adverse event), CR ( complete response), DOCB ( duration of clinical benefit), DOR ( duration of response), MF ( mycosis fungoides), mSWAT ( modified severity weighted assessment tool), ORR ( overall response rate), PD ( progressive disease), PR ( partial response), TSEBT ( total skin electron beam therapy), TTP ( time to progression), TTR ( time to response)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Swerdlow S.
        • Campo E.
        • Harris N.
        • et al.
        World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues.
        4th ed. IARC Press, Lyon2008
        • Criscione V.
        • Weinstock M.
        Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.
        Arch Dermatol. 2007; 143: 854-859
        • Olsen E.
        • Vonderheid E.
        • Pimpinelli N.
        • et al.
        Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).
        Blood. 2007; 110: 1713-1722
        • AJCC
        AJCC cancer staging manual.
        Springer, New York2010
      1. National Comprehensive Cancer Network. Non-Hodgkin's lymphoma (Version 4.2014). http://www.nccn.org/about/nhl.pdf. Accessed November 4, 2014.

        • Kim Y.
        • Liu H.
        • Mraz-Gernhard S.
        • Varghese A.
        • Hoppe R.
        Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression.
        Arch Dermatol. 2003; 139: 857-866
        • Jones G.
        • Hoppe R.
        • Glatstein E.
        Electron beam treatment for cutaneous T-cell lymphoma.
        Hematol Oncol Clin North Am. 1995; 9: 1057-1076
        • Lo T.
        • Salzman F.
        • Wright K.
        Dose considerations in total skin electron radiation in mycosis fungoides.
        Am J Roentgenol. 1979; 132: 261-263
        • Hoppe R.
        Mycosis fungoides: radiation therapy.
        Dermatol Ther. 2003; 16: 347-354
        • Becker M.
        • Hoppe R.
        • Knox S.
        Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides.
        Int J Radiat Oncol Biol Phys. 1995; 32: 1445-1449
        • Wilson L.
        • Quiros P.
        • Kolenik S.
        • et al.
        Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma.
        J Am Acad Dermatol. 1996; 35: 69-73
        • Harrison C.
        • Young J.
        • Navi D.
        • et al.
        Revisiting low dose total skin electron beam therapy in mycosis fungoides.
        Int J Radiat Oncol Biol Phys. 2011; 81: e651-e657
        • Hoppe R.
        • Fuks Z.
        • Bagshaw M.
        Radiation therapy in the management of cutaneous T-cell lymphoma.
        Cancer Treat Rep. 1979; 63: 625-632
        • Olsen E.
        • Whittaker S.
        • Kim Y.
        • et al.
        Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer.
        J Clin Oncol. 2011; 29: 2598-2607
        • Zackheim H.
        • Kashani-Sabet M.
        • Amin S.
        Topical corticosteroids for mycosis fungoides: experience in 79 patients.
        Arch Dermatol. 1998; 134: 949-954
        • Kim Y.
        • Martinez G.
        • Varghese A.
        • Hoppe R.
        Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
        Arch Dermatol. 2003; 139: 165-173
        • Gathers R.
        • Scherschun L.
        • Malick F.
        • Fivenson D.
        • Lim H.
        Narrowband UVB phototherapy for early-stage mycosis fungoides.
        J Am Acad Dermatol. 2002; 47: 191-197
        • Duvic M.
        • Martin A.
        • Kim Y.
        • et al.
        Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
        Arch Dermatol. 2001; 137: 581-593
        • Olsen E.
        • Kim Y.
        • Kuzel T.
        • et al.
        Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
        J Clin Oncol. 2007; 25: 3109-3115
        • Kamstrup M.
        • Lindahl L.
        • Gniadecki R.
        • et al.
        Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study.
        Br J Dermatol. 2011; 166: 399-404